Insider
Amgen IncAMGN

Amgen reports $3.7 billion in free cash flow for the third quarter of 2026

Amgen generated $3.7 billion of free cash flow in the third quarter of 2026, down from $4.2 billion in the third quarter of 2025. This reflects changes in working capital and current period business performance.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
macro photography of glasses on tray
Photo by Nastya Dulhiier on Unsplash
$3.7 billion
Free cash flow
$54.0 billion
Total debt
$13.2 billion
Cash on hand

Key points

  • Sales of key Amgen drugs varied: Prolia revenue fell 45% to $632 million due to global biosimilar launches.
  • The company is consulting with the Food and Drug Administration (FDA) on the voluntary withdrawal of TAVNEOS from the U.S. market, though the outcome of hearings is pending.

Financial results

Sales of key Amgen drugs varied: Prolia revenue fell 45% to $632 million due to global biosimilar launches. Meanwhile, sales of Repatha, Uplizna, and Imdelltra rose 37%, 191%, and 128%, respectively. As of September 30, 2026, the company held $13.2 billion in cash against $54.0 billion in total debt. The company did not repurchase shares during the quarter.

Revenue by quarter and the company's guidance, $B

9.1Q4 '24*25.4%8.1Q1 '2514.5%9.2Q2 '2528.9%9.6Q3 '2526.4%9.9Q4 '25*27.6%8.6Q1 '2630.9%10.1Q2 '2635%10.4Q3 '2635.8%ImpliedQ4 '26
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Regulatory and manufacturing risks

The company is consulting with the Food and Drug Administration (FDA) on the voluntary withdrawal of TAVNEOS from the U.S. market, though the outcome of hearings is pending. Clinical trials of subcutaneous blinatumomab remain under a partial clinical hold by the regulator. A further risk factor is the company's reliance on manufacturing sites in Puerto Rico and third-party contractors, which may constrain product supply.

What to watch

Investors should monitor filings with the Securities and Exchange Commission (SEC) to assess the impact of competition on Prolia sales. It is important to watch for news regarding the status of TAVNEOS and the potential lifting of partial clinical holds on blinatumomab programs.

Original sources

  1. 8-K EX-99.1 filing, November 3, 2026November 3, 2026SHA-256 of our archived copy fa9837435400…
  2. 8-K filing, November 3, 2026November 3, 2026SHA-256 of our archived copy a1584c275545…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards